Act on COPD | HCP information & resources

It’s never too early to

Put prevention of exacerbation and early death at the centre of COPD management.

References:

1. Web log. American Lung Foundation (blog), February 13, 2023. https://www.lung.org/blog/heart-lung-relationship. 2. Watz H, et al. Respir Res 2018;19:251; 3. Suissa S, et al. Thorax 2012;67:957–963; 4. Donaldson GC, et al. Chest 2010;137:1091–1097; 5. Kunisaki KM, et al. Am J Respir Crit Care Med 2018;198:51–57; 6. Rothnie KJ, et al. Am J Respir Crit Care Med 2018;198:464–471; 7. Hurst JR, et al. Eur J Int Med 2020;73:1–6; 8. Pullen R, et al. Int J Chron Obstruct Pulmon Dis 2021;16:2301–2322; 16:3009-3016; 9. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for prevention, diagnosis and management of COPD. 2024. Available from: https://goldcopd.org/2024-gold-report/ (Accessed March 2024); 10. Müllerová H, et al. BMJ Open 2014;4:e006171; 11. Hughes R, et al. Respir Med 2022;200:106921; 12. Singh D et al. International Journal of Chronic Obstructive Pulmonary Disease 2021:16 3009–30164 13. Barnes N, et al. BMC Pulm Med. 2013;13:54. 14. Pavord ID, et al. Int J Chron Obstruct Pulmon Dis. 2016;11(special issue):21-30. 15. Graul EL, et al. Am J Respir Crit Care Med 2023; doi: 10.1164/rccm.202307-1122OC: Dec 21 [Epub ahead of print]. 16. Adeloye D et al. Lancet Resp Med. 2022;10:447-458. 17. Hurst JR, et al. N Engl J Med. 2010;363(12):1128-1138. 18. ClinicalTrials.gov. NCT00292552. Last date of access: March 2024. 19. Wallace AE, et al. J Manag Care Spec Pharm. 2019;25(2):205-217. 20. Koblizek V, et al. Eur Respir J. 2017;49(5):1601446. 21. Jones PW, et al. Am J Respir Crit Care Med. 2015;191:A2532. 22. Matsunaga K, et al. Respir Investig. 2015;53(2):82-85. 23. Hoogendoorn M, et al. Int J Chron Obstruct Pulmon Dis. 2017;12:3183-3194. 24. Tashkin DP, et al. N Engl J Med. 2008;359(15):1543-1554. 25. Roche N, et al. Eur Resp J. 2017;50:OA1487. 26. Kania A, et al. Int J Chron Obstruct Pulmon Dis. 2018;13:1613-1621. 27. Halpin DMG, et al. Respir Med. 2017;128:85–91. 28. Rothnie KJ et al. Ann Am Thorac Soc. 2018 Aug;15(8):935-946. doi: 10.1513/AnnalsATS.201710-815OC. PMID: 29723057; PMCID: PMC6322039. 29. Mannino DM, et al. Respir Med 2006;100:115–122. 30. Hughes R, et al. Respir Med 2022;200:106921 31. Bafadhel M, et al. Lancet Respir Med. 2018;6:117-126. 32. Lindberg A et al. Respir Med. 2015;109:88–95. 33. Dransfield MT, et al. Am J Respir Crit Care Med. 2017;195(3):324-330. 34. Westerik JAM, et al. Respir Res. 2017;18:31. 35. Kessler R, et al. CHEST. 2006;130(1):133–142.

*In some patients, lung function did not recover to pre-exacerbation levels by eight weeks after the start of the moderate exacerbation

†following a severe exacerbation, the rate of severe exacerbation increased and the time to subsequent exacerbations decreased

‡Singh, D., Han, M.K., Hawkins, N.M. et al. Implications of Cardiopulmonary Risk for the Management of COPD: A Narrative Review. Adv Ther (2024).
https://doi.org/10.1007/s12325-024-02855-4

**In a study conducted on patients with moderately severe COPD and rigorously adjudicated CVD events

***Cohort study that evaluated severe COPD exacerbations and their association with mortality in 73106 patients with their first severe COPD exacerbation requiring hospitalisation. Patients with data available between 1990 and 2005 were identified and followed until death or 31 March 2007

****Irreversibly reduce lung function

*****The relative risk of MI returned to near baseline, similar to any other post exacerbation time interval

THIS SITE IS INTENDED FOR HEALTHCARE PROFESSIONALS. ACT ON COPD IS A NON-PROMOTIONAL PROGRAM INITIATED, DEVELOPED AND FUNDED BY ASTRAZENECA

ASTRAZENECA VPN ID: Z4-64729
DATE OF PREPARATION: MAY 2024
DATE OF EXPIRY: MAY 2026

ASTRAZENECA VPN ID: Z4-64729AstraZeneca VPN ID: Z4-64476
DATE OF PREPARATION: MAY 2024DATE OF PREPARATION: MAY 2024
DATE OF EXPIRY: MAY 2026DATE OF EXPIRY: MAY 2026